SYNCAR 001
Alternative Names: Orthogonal IL-2 receptor-modified CD-19 targeted CAR-T - Synthekine; STK 009/SYNCAR 001; STK-009 + SYNCAR-001; SYNCAR-001Latest Information Update: 06 Sep 2024
At a glance
- Originator Synthekine
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Interleukins
- Mechanism of Action Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Haematological malignancies
- Preclinical Lupus nephritis; Systemic lupus erythematosus
- No development reported Cancer; Lymphoma
Most Recent Events
- 04 Sep 2024 SYNCAR 001 receives Fast track status from the US FDA for Systemic lupus erythematosu
- 28 Jul 2024 No recent reports of development identified for preclinical development in Cancer in USA (SC)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Lymphoma in USA (SC)